Clinical Trials for Karuna Therapeutics

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Karuna Therapeutics

Clinical Trials (8)

NCT07204418
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
PHASE1Not yet recruiting
56 participants
Started: Oct 14, 2025 · Completed: Dec 3, 2026
1 condition1 sponsor3 locations
NCT07118215
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
PHASE1Not yet recruiting
60 participants
Started: Sep 9, 2025 · Completed: Apr 5, 2026
1 condition1 sponsor1 location
NCT06729970
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
PHASE1Recruiting
130 participants
Started: Dec 26, 2024 · Completed: Jan 18, 2026
1 condition1 sponsor1 location
NCT06585787
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
PHASE3Recruiting
406 participants
Started: Sep 26, 2024 · Completed: Oct 19, 2026
1 condition1 sponsor254 locations
NCT06126224
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
PHASE3Active, not recruiting
400 participants
Started: Aug 28, 2023 · Completed: Jul 31, 2025
1 condition1 sponsor119 locations
NCT05980949
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT and KarXT + KarX-EC in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
PHASE3Recruiting
800 participants
Started: Jul 11, 2023 · Completed: Sep 7, 2027
1 condition1 sponsor392 locations
NCT05511363
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
PHASE3Recruiting
380 participants
Started: Aug 23, 2022 · Completed: Oct 5, 2026
1 condition1 sponsor116 locations
NCT05304767
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
PHASE3Recruiting
280 participants
Started: Mar 7, 2022 · Completed: Mar 19, 2026
1 condition1 sponsor175 locations